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Abstract
Background: Our previous study showed a close relationship between computed tomography (CT)-derived
bidimensional measurement of primary tumor and retropharyngeal nodes (BDMprn) and gross tumor volume of
primary tumor and retropharyngeal nodes (GTVprn) in nasopharyngeal carcinoma (NPC) and better prognosis for
NPC patients with smaller BDMprn. In this study, we report the results on of a study to validate the use of BDM in
a separate cohort of NPC patients.
Methods: We retrospectively reviewed 103 newly diagnosed NPC cases who were treated with radiotherapy/
concurrent chemoradiotherapy (CCRT) or CCRT with adjuvant chemotherapy from 2002 to 2009. We used magnetic
resonance imaging (MRI) to measure BDMprn. We calculated overall survival, recurrence-free and distant metastasis-
free survival curves and set a BDMprn cut off point to categorize patients into a high- or low-risk group. We then
used Cox proportional hazard model to evaluate the prognostic influence of BDMprn after correcting age, gender
and chemotherapy status.
Results: After adjusting for age, gender, and chemotherapy status, BDMprn remained an independent prognostic
factor for distant metastasis [Hazard ratio (HR) = 1.046; P = 0.042] and overall survival (HR = 1.012; P = 0.012).
Patients with BDMprn < 15 cm
2 had a greater 3-year overall survival rate than those with BDMprn ≧ 15 cm
2 (92.3%
vs. 73.7%; P = 0.009). They also had a greater 3-year distant metastasis-free survival (94% vs.75%; P = 0.034).
Conclusion: The predictive ability of BDMprn was validated in a separate NPC cohort. A BDMprn of 15 cm
2 can be
used to separate NPC patients into high- and low-risk groups and predict survival rates and metastasis potential. It
can, therefore, be used as a reference to design clinical trials, predict prognosis, and make treatment decisions.
Background
Nasopharyngeal carcinoma (NPC) is common among
Asians, especially in southern China. While the annual
incidence in Western countries is < 1 per 100,000 popu-
lation, it is 6.17 per 100,000 in Taiwan [1]. Because it is
difficult to approach nasopharyngeal tumors surgically,
chemoradiotherapy or radiotherapy is the primary
means of treating this disease [2]. The American Joint
Committee of Cancer (AJCC) staging system for NPC is
widely used to prognosticate and plan for its treatment
and is well-accepted as an evaluation tool in clinical
research. However, because the current TNM staging
approach is limited in its ability to predict prognosis
based on NPC tumor stage [3,4], other factors might be
incorporated to further refine prognostic accuracy.
Gross tumor volume is one factor closely related to
NPC survival [5-8]. It is not, however, widely advocated
as a prognostic factor probably because measuring
tumor volume can be time-consuming and labor-inten-
sive. Several studies have used unidimensional and bidi-
mensional measurement to evaluate the tumor size
[9-11]. In a previous study, we found bidimensional
measurement of primary NPC tumor and retropharyn-
geal nodes by computed tomography (CT) imaging to
be an independent prognostic factor [12]. Due to its
improved accuracy, magnetic resonance imaging (MRI)
has now virtually replaced CT scan as means of deter-
mining the stage of tumors, including NPC, before they
are treated [13]. MRI is superior to CT scan for diag-
nosing the gross extent of tumor infiltration and retro-
pharyngeal lymph node metastasis.
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in a separate cohort of NPC patients to further validate
of the previous finding regarding the use of bidimen-
sional measurement as means of prognosis in NPC. If
confirmed to be an independent prognostic factor, then
prognostic ability of the current TNM staging approach
can be improved.
Methods
Patient selection
The method of bidimensional measurement of primary
tumor and retropharyngeal nodes (BDMprn) in NPC
was derived from a cohort of newly diagnosed NPC
patients with definite treatment [12]. All patients had
histological confirmed NPC and received CT scan of
the nasopharyngeal area, chest X-ray, ultrasound or
CT scan of the abdomen and whole body bone scan.
All cases were restaged based on criteria outlined in
the 6th edition of the AJCC staging system [14]
Patients received a complete course of radiotherapy
(70 Gy - 75 Gy). Patients who received concurrent
chemoradiotherapy (CCRT) received three cycles of
cisplatin during the same period that were undergoing
radiotherapy. Subsequent adjuvant chemotherapy con-
sisting of cisplatin and 5-FU was arranged as guide-
lines [2]. Using computed tomography-derived
measurement, bidimensional measurement of primary
tumor and retropharyngeal nodes (BDMprn) in NPC
had good correlation with gross tumor volume (Spear-
man’ correlation coefficient = 0.845, P < 0.001). The
intrarater reliability for BDM was good. In multivariate
analysis, BDMprn was an independent prognostic fac-
tor for any relapse [Hazard ratio (HR) = 1.066; P =
0.029], and overall survival [HR = 1.097; P = 0.007].
NPC patients with large BDMprn conferred a poor
survival and more recurrences[12].
Validation of the bidimensional measurement of pri-
mary tumor and retropharyngeal nodes was performed
using a cohort which included NPC patients treated at
Kaohsiung Veterans General Hospital from 2002 to
2009. The means of treating NPC patients in these two
hospitals is similar. All patients received a complete
course of radiotherapy (70 Gy - 75 Gy). Concurrent che-
motherapy was arranged for NPC patients with
advanced T (T2-4) classification or positive neck metas-
tasis. Patients with T2b-T4 or N2-3 disease underwent
subsequent adjuvant chemotherapy.
Before treatment, all NPC patients received physical
examinations, fiberoptic examinations, chest X-rays,
ultrasound or CT scan of the abdomen, whole body
bone scan and MRI of nasopharyngeal area. Similarly,
all cases were restaged according to the AJCC stage
classification system, which was modified in 2002.
MRI technique and measurements
Gross tumor volume of primary tumor and retrophar-
yngeal nodes (GTVprn) of NPC measurement was per-
formed with summation of area technique as described
previously [12]. The lateral retropharyngeal nodes were
considered malignant if its shortest axial dimension
was 5 mm or greater, and any visible node in the med-
ian retropharyngeal group was considered metastatic
[15-17]. Bidimensional measurement of primary tumor
and retropharyngeal nodes (BDMprn) was performed
as described previously [12]. Briefly, BDMprn was
obtained by multiplying the maximum diameter of the
nasopharyngeal tumor and retropharyngeal nodes by
the greatest measurement perpendicular to it (Figure
1). Bidimensional measurement of primary tumor
(BDMp) was calculated by multiplying the maximum
diameter of the nasopharyngeal tumor by the greatest
measurement perpendicular to it [18]. It was some-
times difficult to evaluate the anatomic extent of pri-
mary tumor and retropharyngeal node. In such cases,
when the outline of tumor was unclear, a radiologist
specializing in head and neck cancer helped demarcate
the margin. When there was skull base involvement or
parapharyngeal space invasion, we could measure the
gross tumor and retropharyngeal nodes using the same
methods in Figure 1.
The calculation of the three measurements was as the
followings:
GTVprn = Ʃ Outlined area of primary tumor and ret-
ropharyngeal nodes × (slice thickness + split interval).
BDMprn = Ʃ Maximum diameter × greatest perpendi-
cular of primary tumor and retropharyngeal nodes.
BDMp = Maximum diameter × greatest perpendicular
of primary tumor.
Clinical endpoints
Clinical endpoints were 3-year overall survival, any
recurrence and distant metastasis. Six weeks after com-
pleting the course of treatment, patients received endo-
scopy and biopsy of the nasopharynx if necessary. Two
months after the course of treatment, each patient
received a MRI examination. Chest X-rays, abdominal
sonography, and whole body bone scan were performed
regularly.
Statistics
Intrarater reliability was measured using the intraclass
correlation coefficient. Overall survival, distant metasta-
sis-free survival and recurrence-free survival were calcu-
lated according to the methods of Kaplan and Meier.
Differences between multiple survival curves were com-
pared using the log-rank test. The prognostic influence
of BDM was assessed using Cox proportional hazards
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Figure 1 T2-weighted postcontrast MR image in the axial plane. The bidimensional measurement of primary tumor and retropharyngeal
nodes (BDMprn) was obtained by summation of multiplying the maximum diameter by the greatest measurement perpendicular to it in
nasopharyngeal tumor (A) and retropharyngeal nodes (B). BDMprn (cm
2) = A1 × B1 + A2 × B2 + A3 × B3.
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chemotherapy status. BDM cut-off values were obtained
by receiver operating characteristic (ROC) curve analy-
sis. All statistical operations were performed using the
Statistical Package for Social Sciences, version 15.0
(SPSS, Chicago, IL).
Results
Patient and disease characteristics
The intrarater reliability correlation coefficients for
GTVprn, BDMprn, and BDMp were 0.956(0.935-0.97),
0.964 (0.912-0.986), and 0.966 (0.916-0.987). Table 1
shows the characteristics of patients in validation cohort.
The mean age was 51 ± 13 years. Of the 103 NPC
patients, 77 (75%) patients were men. 88 patients (85%)
had advanced stage (stage III-IV). These NPC patients
were followed up a median of 43 months (range 9-80
months). Thirty-four (33%) in the validation cohort had
recurrences, including 15 (15%) with locoregional recur-
rence and 12 (12%) with distant metastasis. Eighteen
patients (18%) expired. The 3-year overall survival rate
was 87%, locoregional control survival rate 88%, distant
metastasis-free survival rate 89%, and recurrence-free
survival rate 79%.
Univariate and multivariate analysis
Based on our univariate analysis, bidimensional mea-
surement of primary tumor and retropharyngeal nodes
was found to be a significant prognostic factor (Table
2). Adjusting for age, gender, and chemotherapy status,
our multivariate analysis found bidimensional measure-
ment of primary tumor and retropharyngeal nodes to
significantly predict overall survival (HR = 1.012; 95%
CI: 1.014-1.12; P = 0.012) and metastasis-free survival
(HR = 1.046; 95% CI: 1.002-1.121; P = 0.042). The
bidimensional measurement of primary tumor was not
a significant predictor for outcomes in multivariate
analysis. Both univariate and multivariate analysis
found gross tumor volume of primary tumor and ret-
ropharyngeal nodes to be a significant prognostic
factor.
Bidimensional measurement and risk groups
We wanted to further validate the prognostic ability of
bidimensional measurement of primary tumor and ret-
ropharyngeal nodes using MRI findings. After analyzing
trade-off, we chose 15 cm
2 as the cut-off point in the
validation cohort (additional file 1). Using this cut-off
point, we further divided validation cohort into a smal-
l e rB D M p r ng r o u p( 6 7 % )a n dal a r g e rB D M p r ng r o u p
(33%). The smaller BDMprn group had greater 3-year
overall survival, distant metastasis-free survival, and
recurrence-free survival rates than the large BDM
group. (92.3% vs. 73.7%, P = 0.009; 94% vs. 75%, P =
0.034; 64.1% vs. 59.7%, P = 0.082) (Figure. 2A and 2B),
and they were at lower risk.
Discussion
In a previous study, CT-derived bidimensional measure-
ment of primary tumor and retropharyngeal nodes
could be used to predict prognosis of NPC [12]. Using
MRI to validate the ability of bidimensional measure-
ment of primary tumor and retropharyngeal nodes to
predict NPC outcomes in a validation cohort, we found
BDMprn remained an independent prognostic factor for
overall survival as well as metastasis-free survival.
Adopting a BDMprn of 15 cm
2 as cut-off point in vali-
dation cohort, NPC patients whose BDMprn was less
than 15 cm
2 had a better 3-year overall survival rate and
distant metastasis-free survival rate than those with
BDMprn above this cut off point. Based on these two
studies, we have found that BDMprn can be used to
stratify patients into two different prognostic groups
with significantly different overall survival and meta-
static rates.
Table 1 Patient Characteristics
Variables Validation cohort (n = 103)
No. of patients (%)
Age (years)
Mean ± SD 51 ± 13
Gender
Male 77(75)
Female 26(25)
Stage
I 3(3)
II 12(12)
III 56(54)
IV 32(31)
T classification
T1 25(24)
T2 20(19)
T3 34(33)
T4 24(23)
N classification
N0 6(6)
N1 11(11)
N2 72(70)
N3 14(14)
Histology grade
Non-keratinizing carcinoma 13(13)
Undifferentiated carcinoma 90(90)
Treatment modality
RT/CCRT 76(74)
CCRT+CT 27(26)
SD, standard deviation; RT, radiotherapy; CCRT, concurrent
chemoradiotherapy; CCRT+CT, concurrent chemoradiotherapy with adjuvant
chemotherapy
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widely used, it has been reported to have several defi-
ciencies. Mao et al. [3] and Cheng et al. [4] have not
found any significant differences in local-relapse free
survival among the T1, T2, and T3 NPC subgroups.
Recently, gross tumor volume has been reported to be a
risk factor for local recurrence of NPC [5,6,19]. How-
ever, measurement of gross tumor volume is time-con-
suming, and the technology, expertise, and manpower
are often not available in routine clinical practice.
In a study of bidimensional and unidimensional MRI-
derived measurement to reflect NPC tumor anatomic
extent at diagnosis or the change in size after treatment,
King et al. [18] found that BDM of primary tumor was
a quicker and more widely applicable method than
tumor volume measurement and that it could be used
to assess tumor response. However, measurement of ret-
ropharyngeal nodes were not included in that series.
Tang et al. [20] showed that retropharyngeal lymph
node metastasis affects the distant metastasis-free survi-
val rates of NPC, and Wang et al. [21] found a good
correlation between retropharyngeal lymph node metas-
tasis and parapharyngeal space involvement as well as
metastasis to Level II, III, IV and/or V nodes. Based on
these findings, our previous study modified the
approach used by King et al. to include both primary
tumor and retropharyngeal lymph nodes measurements
in our definition of BDM. Previous study found a very
close relationship between CT-derived BDMprn, gross
tumor volume of primary tumor and retropharyngeal
nodes, and overall survival [12]. In the present study,
also incorporating retropharyngeal lymph node mea-
surements, we found MRI-derived BDMprn could also
predict overall survival as well as metastasis free survival
in NPC patients.
In our study, we found that we could use BDMprn to
categorize patients into low- and high-risk groups. This
distinction would facilitate treatment decisions, as it
would spare low-risk NPC patients from receiving
aggressive treatment. Although NPC is markedly
radiosensitive, there is a high failure rate in treatment
due to its metastatic behavior. Improvement in the out-
come for NPC relies on the delivery of higher radiation
doses [22]. While radiotherapy is the only standard
treatment for early-stage NPC (stage I), the combination
of cisplatin-based chemotherapy and radiotherapy is
used to treat patients with advanced NPC (stage II-IVB)
[2]. The latter group not only receives higher doses of
radiotherapy, they also receive chemotherapy, both asso-
ciated with significant comorbidity, including myocardial
infarction, severe nutrient deficiency, nephrotoxicity,
transverse myelitis, leukopenia, and central nervous sys-
tem disease [2,23,24]. Recent study revealed that NPC
patients with GTVprn ≧ 13 ml conferred a poor prog-
nosis and may benefit from ≧ 4c y c l e so fc h e m o t h e r a p y
[25]. This series implied that high-risk NPC patients,
such as large GTVprn, could benefit from more inten-
sive chemotherapy and radiotherapy. The treatment
goals for NPC is to adjust chemoradiotherapy dosages
to achieve adequate anticancer effects without overly
increasing the development of such complications. It
would be important and valuable if high-risk NPC
patients could be identified in order to adjust the radia-
tion dose and tailor chemotherapy protocol. In this way,
high-risk patients (larger BDMprn) may benefit from
more extensive treatment approaches, such as more
intensive chemotherapy or higher dose of radiation,
whereas low-risk patients (smaller BDMprn) may do
well with standard therapy and can be spared the severe
toxic side effects of more radical therapy.
Conclusion
We have validated bidimensional measurement of pri-
mary tumor and retropharyngeal nodes in a different
cohort of NPC with pretreatment staging by MRI.
BDMprn, derived by MRI, is closely related to survival
rates and metastatic rates of NPC patients. BDMprn can
stratify patients into two different prognostic groups
with significantly different overall survival. Nasopharyn-
geal carcinoma patients with large bidimensional
Table 2 Univariate and multivariate analysis results (n = 103)
Overall survival Metastasis Any recurrence
Univariate
HR (95% CI)
Multivariate*
HR (95% CI)
Univariate
HR (95% CI)
Multivariate*
HR (95% CI)
Univariate
HR (95% CI)
Multivariate*
HR (95% CI)
GTVprn 1.07 (1.037-1.103) 1.069 (1.033-1.107) 1.049 (1.013-1.085) 1.05 (1.01-1.091) 1.048 (1.018-1.079) 1.037 (1.004-1.071)
P < 0.001 P < 0.001 P = 0.007 P = 0.013 P = 0.002 P = 0.028
BDMprn 1.071 (1.021-1.122) 1.012 (1.014-1.12) 1.06(1.006-1.116) 1.06 (1.002-1.121) 1.046 (1.002-1.093) 1.038 (0.99-1.088)
P = 0.004 P = 0.012 P = 0.028 P = 0.042 P = 0.041 P = 0.121
BDMp 1.056 (1.001-1.113) 1.048 (0.991-1.108) 1.041 (0.983-1.116) 1.043 (0.981-1.108) 1.043 (0.993-1.096) 1.037 (0.984-1.092)
P = 0.045 P = 0.099 P = 0.169 P = 0.176 P = 0.091 P = 0.173
GTVprn, gross tumor volume of primary tumor and retropharyngeal nodes; BDMprn, bidimensional measurement of primary tumor and retropharyngeal nodes;
BDMp, bidimensional measurement of primary tumor; HR, hazard ratio; 95% CI, 95% confidence interval.
*Multivariate analysis: adjusted for age, gender, and chemotherapy status.
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rates by BDMprn.
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sis potential. BDMprn might be used in the future for
the design of clinical trials, the prediction of survival,
and treatment decisions.
Additional material
Additional file 1: Table S1. Validity of BDMprn using death, distant
metastasis or any recurrence as the standard.
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